KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors
October 22, 2024 07:00 ET
|
KSQ
KSQ Therapeutics Appoints John Lepore, M.D., to its Board of Directors
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
October 08, 2024 07:00 ET
|
KSQ
KSQ Therapeutics Appoints Anna Truppel-Hartmann, M.D., as Chief Medical Officer
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
September 24, 2024 07:00 ET
|
KSQ
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-004EX, a CRISPR/Cas9 Engineered Tumor-Infiltrating Lymphocyte (eTIL®) Therapy
KSQ Therapeutics to Participate in Upcoming Investor Conferences
August 28, 2024 07:00 ET
|
KSQ
KSQ Therapeutics to Participate in Upcoming Investor Conferences
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
June 12, 2024 07:00 ET
|
KSQ
KSQ Therapeutics Announces First Patient Dosed in Clinical Development Program for KSQ-001EX, a CRISPR/Cas9 Engineered eTIL® Therapy
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy
November 29, 2023 07:00 ET
|
KSQ
KSQ Therapeutics Announces FDA Clearance of IND Application for KSQ-001EX, a CRISPR/Cas9 Engineered Tumor Infiltrating Lymphocyte (eTIL®) Therapy